Products You May Like
CALGARY, Alberta, June 17, 2021 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Firm”) (CSE: XRX; OTCQB: XRTXF), a biotechnology firm targeted on creating modern therapies to deal with progressive kidney illness, is happy to announce the appointment of Jacqueline Le Saux to the Firm’s board of administrators and the resignation of Allan Williams. Ms. Le Saux is a seasoned Canadian well being care authorized government who has held senior positions at massive and small private and non-private life science corporations. Jacqueline’s authorized expertise is concentrated on securities, pharmaceutical regulatory and mental property legislation.
Dr. Allen Davidoff, President and CEO of XORTX said, “Jaqueline Le Saux brings to the XORTX board of administrators an skilled authorized and strategic perspective and a observe file of success in worth creation, threat administration and ethics and company governance. We’re happy to achieve the depth of expertise and expertise that she is going to carry to our board,” Dr. Davidoff added, “On behalf of the Board of Administrators and myself, we thank Allan Williams for his many contributions on behalf of XORTX and acknowledge the essential optimistic influence Allan has had on the expansion and success of the corporate up to now.”
Jacqueline Le Saux commented, “It’s an honor and privilege to hitch the XORTX board at this pivotal stage of the Firm’s growth. Kidney illness impacts thousands and thousands of sufferers world wide and I’m happy to be taking part, by means of the XORTX board, within the growth of therapies designed to handle the unmet wants of those sufferers.”
In reference to the appointment of Jacqueline Le Saux, XORTX has granted, in accordance with the Firm’s inventory possibility plan, an combination of 250,000 choices to buy widespread shares of the Firm at an exercisable worth of $0.15 for a interval of 5 years.
About Jacqueline Le Saux
As a Vice President, Authorized in each private and non-private corporations Ms. Le Saux has led a number of financings, mergers and acquisitions and product licensing transactions, mitigating threat and executing methods within the Canadian healthcare trade. Her broad trade expertise spans massive pharma to early and late-stage analysis and growth, in addition to shopper merchandise and pharmaceutical manufacturing. Previous to getting into the well being care trade, she was a companion at a high tier Canadian legislation agency, specializing in securities and company legislation. Jacqueline is now transitioning to the position of an impartial Company Director.
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a biotechnology firm with three clinically superior merchandise in growth – XRx-008 for Autosomal Dominant Polycystic Kidney Illness (ADPKD), XRx-101 for Coronavirus / COVID-19 an infection and XRx-225, a pre-clinical stage program for Sort 2 Diabetic Nephropathy (T2DN). The Firm has mental property rights and has established proof of idea by means of impartial scientific research. XORTX is working to advance its scientific growth stage merchandise that concentrate on xanthine oxidase to inhibit manufacturing of uric acid. At XORTX Therapeutics, we’re devoted to creating drugs to enhance the standard of life and way forward for sufferers affected by kidney illness. Extra data on XORTX Therapeutics is on the market at www.xortx.com.
For additional data, please contact:
Neither the Canadian Securities Trade, nor some other Canadian, US or different international inventory alternate, securities fee or different regulatory authority has accepted or disapproved the knowledge contained herein.
